Amgen (AMGN) Says New Data Shows Aimovig Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) today announced new data in patients with high unmet need, providing further evidence of the efficacy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
